Amgen Inc. is one of the world's leading biotechnology companies. Founded in 1980 in the United States, it currently operates in more than 70 countries around the world.

Amgen focuses on developing cutting-edge medicines against cancer, cardiovascular diseases, bone ailments, kidney diseases and other afflictions.

The company currently has a market capitalization of $122.5 billion. Amgen reported revenues of $25.98 billion and a net income of $5.89 billion in 2021.

Amgen Inc. stock and what affects it

The company stock is listed on the NASDAQ exchange under the ticker name AMGN. When the company had its initial public offering in 1983, its shares were priced between $16 and $19 at the time.

Now, Amgen's shares are trading between $227 and $231. Last year, it fluctuated from $198 to $258. Forecasts suggest the stock will continue to climb.

When trading this asset, you have to keep the following things in mind:

The company has a dominant position in the market.
There are potential opportunities to capitalize on its products and strategic initiatives.
Threats to Amgen include its competition, government regulation, and the company’s dependence on wholesale distributors.